NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
Clinical Trials
9 trialsNCT06217757 2024-05-13
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sichuan University
Phase 1/2 Recruiting
NCT02797977 2023-06-22
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Sierra Oncology LLC - a GSK company
Phase 1/2 Completed
NCT01642251 2023-05-06
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00453154 2023-04-04
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01859741 2020-09-09
PINNACLE
Mereo BioPharma
Phase 1/2 Terminated
NCT00401609 2016-01-14
G-Step
National Cancer Institute, Naples
Phase 1/2 Completed
NCT00359359 2014-11-04
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer
Bayer
Phase 1/2 Completed
NCT00447421 2009-10-28
A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy
Eli Lilly and Company
Phase 1/2 Terminated